Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

British Journal of Cancer

Volumn 105, Issue 3, 2011, Pages 372-381

  Peasland, A ^a   Wang, L Z ^a   Rowling, E ^a   Kyle, S ^a   Chen, T ^a   Hopkins, A ^a   Cliby, W A ^b   Sarkaria, J ^b   Beale, G ^a   Edmondson, R J ^a   Curtin, N J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 2,6 DIAMINO 4 CYCLOHEXYLMETHYLOXY 5 NITROSOPYRIMIDINE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ATR PROTEIN; CAMPTOTHECIN; CHECKPOINT KINASE 1; CISPLATIN; CYCLIN DEPENDENT KINASE 2 INHIBITOR; DOXYCYCLINE; FLUOROURACIL; HYDROXYUREA; METHYLNITRONITROSOGUANIDINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PF 01367338; PROTEIN INHIBITOR; PROTEIN P53; PYRIMIDINE DERIVATIVE; RAD51 PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN A2780; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MISMATCH REPAIR; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA DAMAGE; DNA MISMATCH REPAIR; DRUG EVALUATION, PRECLINICAL; FEMALE; GENES, P53; HUMANS; LEUKEMIA L1210; MICE; NITROSO COMPOUNDS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES;

EID: 79960834396     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.243     Document Type: Article

References (57)

1. Alano CC, Kauppinen TM, Valis AV, Swanson RA (2006) Minocyclin inhibits poly (ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 103(25): 9685-9690 (Pubitemid 43955885)
2. Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble ME, Sausville EA, Schultz R, Yu W (2000) Interfacing cell line screening and structural biology in drug discovery: the identification of a novel class of antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumour cell growth inhibition profiles. J Med Chem 43: 2797-2804 (Pubitemid 30599637)
3. Ashwell S, Janetka JW, Zabludoff S (2008) Keeping checkpoint kinases in line: new selective inhibitors in clinical trial. Expert Opinion Invest Drugs 17: 1331-1340
4. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF (1987) Characterisation of a cis-diamminedichloroplatinum II resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47(2): 414-418 (Pubitemid 17009602)
5. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, O'Connor P, Anderes K (2008) Breaching the DNA damage checkpoint via PF-00477736, a novel small molecule inhibitor of checkpoint kinase 1. Mol Can Ther 7(8): 2394-2404
6. Brown EJ, Baltimore D (2000) ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Develop 14: 397-402 (Pubitemid 30131885)
7. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtsek B, Kaye SB (1993) Increased accumulation of p 53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678-684 (Pubitemid 23328959)
8. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase. Nature 434: 913-917 (Pubitemid 40559005)
9. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J, D'Atri S (2004) DNA damage induced by temozolomide signals to both ATM and ATR: role of mismatch repair system. Mol Pharmacol 66: 478-491 (Pubitemid 39329246)
10. Charrier J-D, Durrant SJ, Golec JMC, Kay DP, Knegtel RM, MacCormick S, Mortimore M, O'Donnell ME, Pinder JL, Reaper PM, Rutherford AP, Wang PS, Young SC, Pollard JR (2011) Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad 3 related (ATR) protein kinase as potential anticancer agents. J Med Chem 54: 2320-2330
11. Chen J (2000) Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. Cancer Res 60: 5037-5039
12. Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, Li G, Wang G, Tao ZF, Tong Y, Lin NH, Sham HL, Wang JY, Sowin TJ, Rosenberg SH, Zhang H (2006) Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 119: 2784-2794 (Pubitemid 44846229)
13. Cliby WA, Lewis KA, Lilly KK, Kaufmann SH (2002) S-Phase and G2 arrest induced by topoisomerase I posons are dependent on ATR kinase function. J Biol Chem 277: 1599-1606 (Pubitemid 34968919)
14. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, Friend SH (1998) Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA damaging agents and defects in cell cycle checkpoints. EMBO J 17: 159-169 (Pubitemid 28041057)
15. Cui B, Johnson SP, Bullock N, Ali-Osman F, Bigner DD, Friedman HS (2009) Bifunctional DNA-alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. Mol Pharmacol 75: 1356-1383
16. Dai Y, Grant S (2010) New insights into checkpoint kinase I in the DNA damage response signalling network. Clin Can Res 16: 376-383
17. Garber K (2005) New checkpoint blockers begin human trials. J Natl Cancer Inst 97: 1026-1028 (Pubitemid 41417914)
18. Griffin RJ, Srinivasan S, Bowman K, Calvert AH, Curtin NJ, Newell DR, Pemberton LC, Golding BT (1998) Resistance-modifying agents. 5. Synthesis and biological properties of quinazoline inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J Med Chem 41: 5247-5256 (Pubitemid 29016316)
19. Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319: 1352-1355 (Pubitemid 351354863)
20. Harrison LRE, Ottley CJ, Pearson DG, Roche C, Wedge SR, Dolan ME, Newell DR, Tilby MJ (2009) The kinase inhibitor O6-cyclohexylmethy-lyguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect on CDK2. Biochem Pharmacol 77: 1586-1592
21. Harrison LRE (2009) Optimising treatment with combinations of novel anti-kinase drugs and cytotoxic therapy. PhD thesis, Newcastle University
22. Izzard RA, Jackson SP, Smith GC (1999) Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Can Res 59: 2581-2586 (Pubitemid 29269102)
23. Jackson SP, Bartek J (2009) The DNA damage response in human biology and disease. Nature 461: 1071-1078
24. Jacobson EL, Jacobson MK (1997) Tissue NAD as a biochemical measure of niacin status in humans. Methods Enzymol 280: 221-230 (Pubitemid 28182358)
25. Kastan MB, Bartek J (2004) Cell cycle checkpoints and cancer. Nature 432: 316-323
26. Kimple RJ, Vaseva AC, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, Sartor CI (2010) Radiosensitization of epidermal growth factor/HER (2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Can Res 16: 912-923
27. Kiyohara C, Takayama K, Nakanishi Y (2006) Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta analysis. Lung Cancer 54: 267-283 (Pubitemid 44634141)
28. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signalling. Cell 125: 733-747
29. Kraakman-van der Zwet M, Wiegant WW, Zdzienicka MZ (2003) Brca2 (XRCC11) deficiency results in enhanced mutagenesis. Mutagenesis 18: 521-525 (Pubitemid 37461553)
30. Liu Y, Fang Y, Shao H, Lindsey-Boltz L, Sancar A, Modrich P (2010) Interactions of human mismatch repair proteins MutSa and MutLa with proteins of the ATR-CHK1 pathway. J Biol Chem 285: 5074-5082
31. Lu X-L, Errington J, Curtin NJ, Lunec J, Newell DR (2001) The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res 7: 2114-2123 (Pubitemid 32994852)
32. Ma CX, Janetka JW, Piwnica-Worms H (2011) Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 17: 1788-1796
33. Massague J. G1 cell cycle control and cancer. Nature (2004); 432: 298-306
34. Mukhopadhyay A, Elatter A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ (2010) Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to PARP inhibitors. Clin Cancer Res 16: 2344-2351
35. Neijenhuis S, Verwijs-Janssen M, van den Broek LJ, Begg AJ, Vens C (2010) Targeted radiosensitization of cells expressing truncated DNA polymerase b. Cancer Res 70: 8706-8714
36. Nghiem P, Park PK, Kim Y-S, Vaziri C, Schreiber SL (2001) ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci USA 98: 9092-9097 (Pubitemid 32743874)
37. O'Connell MJ, Cimprich KA (2005) G2 damage checkpoints: what is the turn-on? J Cell Sci 118: 1-6 (Pubitemid 40277099)
38. Petermann E, Caldecott KW (2006) Evidence that the ATR/CHK1 pathway maintains normal replication fork progression during unperturbed S phase. Cell Cycle 5: 2203-2209 (Pubitemid 44546554)
39. Plumb JA, Aherne W, Lee D, Westwood N, O'Brien V, McDonald E, Brown R (2006) MMR201: a novel small molecule that selectively inhibits growth of MLH1 deficient tumor cells. Proc Am Assoc Cancer Res 47, Abs 2435
40. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, Margison GP, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert AH, Harris AL, Newell DR, Curtin NJ (2005) Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly (ADP-ribose) polymerase-1. Cancer Res 11: 3402-3409 (Pubitemid 40627893)
41. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, Golec JM, Pollard JR (2011) Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol; e-pub ahead of print 13 April 2011
42. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB (2009) Exploiting synthetic lethality for targeted cancer therapy. Cell Cycle 8: 3112-3119
43. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT (1999) Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59: 4375-4382 (Pubitemid 29418757)
44. Shrivastav M, De Haro LP, Nickoloff JA (2008) Regulation of DNA double-strand break repair pathway choice. Cell Res 18: 134-147
45. Sorensen CS, Hansen LT, Dzigielowski J, Syljuaisen RG, Lundin C, Bartek J, Helleday T (2005) The cell-cycle checkpoint kinase CHK1 is required for mammalian homologous recombination repair. Nature Cell Biol 7: 195-201 (Pubitemid 40268135)
46. Starcevic D, Dalal S, Sweasy JB (2004) Is there a link between DNA polymerase beta and cancer? Cell Cycle 3: 998-1001 (Pubitemid 40268650)
47. Strathdee G, MacKean MJ, Illand M, Brown R (1999) A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341 (Pubitemid 29192710)
48. Thompson LH, Rubin JS, Cleaver JE, Whitmore GF, Brookman KA (1980) screening method for isolating DNA repair-deficient mutants of CHO cells. Somatic Cell Genet 6: 391-405 (Pubitemid 10113596)
49. Vilenchik MM, Knudson AG (2003) Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci USA 100: 12871-12876 (Pubitemid 37339992)
50. Wagner JM, Kaufmann SH (2010) Prospects for the use of ATR inhibitors to treat cancer. Pharmaceuticals 3: 1311-1334
51. Wang H, Wang H, Powel SN, Iliakis G, Wang Y (2004) ATR affecting cell radiosensitivity is dependent on homologous recombination but independent of non-homologous end joining. Cancer Res 64: 7139-7143 (Pubitemid 39331028)
52. Wang Y, Qin J (2003) MSH2 and ATR form a signalling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci USA 100: 15387-15392 (Pubitemid 38020999)
53. Ward IM, Minn K, Chen J (2004) UV-induced ataxia telangiectasia mutated and RAD3-related (ATR) activation requires replicative stress. J Biol hem 279: 9677-9680 (Pubitemid 38372562)
54. Yamane K, Taylor K, Kinsella TJ (2004) Mismatch repair-mediated G2/M arrest by 6-thioguanine involves the ATR-CHK1 pathway. Biochem Biophys Res Commun 318: 297-302 (Pubitemid 38526279)
55. Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, Kuszpit K, Zasadny K, Hallin M, Hallin J, Wong A, Buckman D, Sun G, Qiu M, Anderes K, Christensen JG (2009) PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin Can Res 15: 4630-4640
56. Zhang H, Chen D, Ringler J, Chen W, Cui QC, Ethier SP, Dou QP, Wu G (2010) Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Can Res 70: 3996-4004
57. Zou L, Elledge SJ (2003) Sensing DNA damage through ATRIP recognition of RPA ssDNA complexes. Science 300: 1542-1548 (Pubitemid 36682880)